This separation of astrocytomas into IDHwt and mutated type tumors implies that all hospitals should have access to adequate molecular tests to identify cases of astrocytomas with noncanonical IDH mutations that will not be detected by IDHR132H. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).